Articles published by EpiBiologics

EpiBiologics Closes $107M Series B to Advance Pipeline of Novel Bispecific Antibodies to Selectively Degrade Extracellular Protein Targets in Oncology and Immunology

January 08, 2026

From EpiBiologics

Via Business Wire

EpiBiologics Presents First Data on c-Met Degrading Bispecific Antibody

April 28, 2025

From EpiBiologics

Via Business Wire

EpiBiologics to Present Data Demonstrating Disease-Selective Extracellular Protein Degradation and Platform Breadth at Upcoming Scientific Meetings

November 04, 2024

From EpiBiologics

Via Business Wire

EpiBiologics Extracellular Protein Degraders Demonstrate Robust Preclinical Anti-tumor Activity and Survival Benefit

April 08, 2024

From EpiBiologics

Via Business Wire

EpiBiologics Appoints Ann Lee-Karlon as Chief Executive Officer and President, Extends Series A Financing to Over $70 Million

July 20, 2023

From EpiBiologics

Via Business Wire

EpiBiologics Launches with $50 million Series A Financing to Advance Next-Generation Protein Degradation Platform

March 22, 2023

From EpiBiologics

Via Business Wire

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.